Source
koreabiomed
Medison Pharma’s Amvuttra (vutrisiran) has entered Korea’s reimbursement system for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), raising expectations that the RNA interference-based therapy could improve treatment access and encourage earlier diagnosis of a rare but rapidly progressive disease.
The company held a press conference in Seoul on Wednesday to mark the local reimbursement of Amvuttra for hATTR-PN.
출처 : KBR(https://www.koreabiomed.com)
News Url